Literature DB >> 26753991

First recurrence of Clostridium difficile infection: clinical relevance, risk factors, and prognosis.

T Larrainzar-Coghen1, D Rodriguez-Pardo2, M Puig-Asensio1, V Rodríguez3, C Ferrer1, R Bartolomé3, C Pigrau1, N Fernández-Hidalgo1, T Pumarola3, B Almirante1.   

Abstract

Therapy for recurrent Clostridium difficile-associated diarrhea (CDAD) is challenging. We evaluated the frequency, associated risk factors, and prognosis of first CDAD recurrences. Prospective cohort study of all consecutive cases of primary CDAD diagnosed in a university hospital from January 2006 to June 2013. Recurrent infection was defined as reappearance of symptoms within 8 weeks of the primary diagnosis, provided that CDAD symptoms had previously resolved and a new toxin test was positive. Predictors of a first episode of recurrent CDAD were determined by logistic regression analysis. In total, 502 patients (51.6 % men) with a mean age of 62.3 years (SD 18.5) had CDAD; 379 (76 %) were cured, 61 (12 %) had a first recurrence, 52 (10 %) died within 30 days of the CDAD diagnosis, nine (2 %) required colectomy, and one was lost to follow-up. Among the 61 patients with a first recurrence, 36 (59.3 %) were cured, 15 (23.7 %) had a second recurrence, nine (15.3 %) died, and one (1.7 %) required colectomy. On multivariate analysis, age older than 65 years (OR 2.04; 95 % CI, 1.14-3.68; P < 0.02) and enteral nutrition (OR, 3.62; 95%CI, 1.66-7.87; P < 0.01) were predictors of a first recurrence. A risk score was developed for first CDAD recurrence using the predictive factors and selected biological variables. In our CDAD cohort, 12 % of patients had a first recurrence of this disease, in which the prognosis was less favorable than that of the primary episode, as it heralded a higher risk of additional recurrences. Patient age and enteral nutrition were predictors of a first recurrence.

Entities:  

Mesh:

Year:  2016        PMID: 26753991     DOI: 10.1007/s10096-015-2549-9

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  32 in total

1.  Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection.

Authors:  Mary Y Hu; Kianoosh Katchar; Lorraine Kyne; Seema Maroo; Sanjeev Tummala; Valley Dreisbach; Hua Xu; Daniel A Leffler; Ciarán P Kelly
Journal:  Gastroenterology       Date:  2008-12-13       Impact factor: 22.682

2.  Predicting a complicated course of Clostridium difficile infection at the bedside.

Authors:  M P M Hensgens; O M Dekkers; A Goorhuis; S LeCessie; E J Kuijper
Journal:  Clin Microbiol Infect       Date:  2013-11-04       Impact factor: 8.067

3.  Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection.

Authors:  Kevin A Brown; Nagham Khanafer; Nick Daneman; David N Fisman
Journal:  Antimicrob Agents Chemother       Date:  2013-03-11       Impact factor: 5.191

4.  Epidemiological study of Clostridium difficile infection in critical patients admitted to the Intensive Care Unit.

Authors:  F Alvarez-Lerma; M Palomar; A Villasboa; J Amador; J Almirall; M P Posada; M Catalan; C Pascual
Journal:  Med Intensiva       Date:  2014-02-03       Impact factor: 2.491

Review 5.  Best strategies in recurrent or persistent Clostridium difficile infection.

Authors:  Christine S Cocanour
Journal:  Surg Infect (Larchmt)       Date:  2011-07-18       Impact factor: 2.150

6.  Proton pump inhibitor use and recurrent Clostridium difficile-associated disease: a case-control analysis matched by propensity score.

Authors:  Yong Gil Kim; David Y Graham; Byung Ik Jang
Journal:  J Clin Gastroenterol       Date:  2012 May-Jun       Impact factor: 3.062

7.  Risk factors for and estimated incidence of community-associated Clostridium difficile infection, North Carolina, USA.

Authors:  Preeta K Kutty; Christopher W Woods; Arlene C Sena; Stephen R Benoit; Susanna Naggie; Joyce Frederick; Sharon Evans; Jeffery Engel; L Clifford McDonald
Journal:  Emerg Infect Dis       Date:  2010-02       Impact factor: 6.883

8.  Predictors of first recurrence of Clostridium difficile infection: implications for initial management.

Authors:  David W Eyre; A Sarah Walker; David Wyllie; Kate E Dingle; David Griffiths; John Finney; Lily O'Connor; Alison Vaughan; Derrick W Crook; Mark H Wilcox; Timothy E A Peto
Journal:  Clin Infect Dis       Date:  2012-08       Impact factor: 9.079

9.  Renal failure and leukocytosis are predictors of a complicated course of Clostridium difficile infection if measured on day of diagnosis.

Authors:  Martijn P Bauer; Marjolein P M Hensgens; Mark A Miller; Dale N Gerding; Mark H Wilcox; Adam P Dale; Warren N Fawley; Ed J Kuijper; Sherwood L Gorbach
Journal:  Clin Infect Dis       Date:  2012-08       Impact factor: 9.079

10.  Outcomes and Risk Factors Associated with Clostridium difficile Diarrhea in Hospitalized Adult Patients.

Authors:  Daniela Zilio Larentis; Regis Goulart Rosa; Rodrigo Pires Dos Santos; Luciano Zubaran Goldani
Journal:  Gastroenterol Res Pract       Date:  2015-05-25       Impact factor: 2.260

View more
  9 in total

1.  Gut metabolites predict Clostridioides difficile recurrence.

Authors:  Jennifer J Dawkins; Jessica R Allegretti; Travis E Gibson; Emma McClure; Mary Delaney; Lynn Bry; Georg K Gerber
Journal:  Microbiome       Date:  2022-06-09       Impact factor: 16.837

2.  Prognosis of Clostridium difficile infection in adult oncohaematological patients: experience from a large prospective observational study.

Authors:  Isabel Ruiz-Camps; Benito Almirante; Thais Larrainzar-Coghen; Dolors Rodríguez-Pardo; Pere Barba; Juan Aguilar-Company; Virginia Rodríguez; Gloria Roig; Carmen Ferrer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-08-02       Impact factor: 3.267

Review 3.  A Comparison of Current Guidelines of Five International Societies on Clostridium difficile Infection Management.

Authors:  Csaba Fehér; Josep Mensa
Journal:  Infect Dis Ther       Date:  2016-07-28

4.  Gene expression profiling in pbMEC - in search of molecular biomarkers to predict immunoglobulin production in bovine milk.

Authors:  M Hillreiner; C Schmautz; I Ballweg; V Korenkova; M W Pfaffl; H Kliem
Journal:  BMC Vet Res       Date:  2017-11-29       Impact factor: 2.741

5.  Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain.

Authors:  Miguel Salavert; Javier Cobo; Álvaro Pascual; Belén Aragón; Stefano Maratia; Yiling Jiang; Susana Aceituno; Santiago Grau
Journal:  Adv Ther       Date:  2018-10-16       Impact factor: 3.845

6.  External validation of two prediction tools for patients at risk for recurrent Clostridioides difficile infection.

Authors:  Tessel M van Rossen; Laura J van Dijk; Martijn W Heymans; Olaf M Dekkers; Christina M J E Vandenbroucke-Grauls; Yvette H van Beurden
Journal:  Therap Adv Gastroenterol       Date:  2021-01-09       Impact factor: 4.409

Review 7.  The prognostic value of toxin B and binary toxin in Clostridioides difficile infection.

Authors:  Salvador López-Cárdenas; Eva Torres-Martos; Juan Mora-Delgado; Juan Manuel Sánchez-Calvo; Marta Santos-Peña; Ángel Zapata López; María Dolores López-Prieto; Salvador Pérez-Cortés; Juan Carlos Alados
Journal:  Gut Microbes       Date:  2021-03-04

8.  Recommendations for the diagnosis and treatment of Clostridioides difficile infection: An official clinical practice guideline of the Spanish Society of Chemotherapy (SEQ), Spanish Society of Internal Medicine (SEMI) and the working group of Postoperative Infection of the Spanish Society of Anesthesia and Reanimation (SEDAR).

Authors:  E Bouza; J M Aguado; L Alcalá; B Almirante; P Alonso-Fernández; M Borges; J Cobo; J Guardiola; J P Horcajada; E Maseda; J Mensa; N Merchante; P Muñoz; J L Pérez Sáenz; M Pujol; E Reigadas; M Salavert; J Barberán
Journal:  Rev Esp Quimioter       Date:  2020-02-20       Impact factor: 1.553

9.  Economic burden of recurrent Clostridioides difficile infection in adults admitted to Spanish hospitals. A multicentre retrospective observational study.

Authors:  E Bouza; J Cobo; M J Rodríguez-Hernández; M Salavert; J P Horcajada; J A Iribarren; E Obi; V Lozano; S Maratia; M Cuesta; E Uría; E Limón
Journal:  Rev Esp Quimioter       Date:  2021-02-23       Impact factor: 1.553

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.